Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy
- 1 January 2017
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 18 (1) , e35-e40
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant DiseaseJournal of Clinical Oncology, 2013
- Uptake of Oxaliplatin and Bevacizumab for Treatment of Node-Positive and Metastatic Colon CancerJournal of Oncology Practice, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung AdenocarcinomasJournal of Clinical Oncology, 2011
- Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor ReceptorsJournal of Thoracic Oncology, 2010
- Gender, Histology, and Time of Diagnosis Are Important Factors for Prognosis: Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in JapanJournal of Thoracic Oncology, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in JapanJournal of Clinical Oncology, 2008
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005